%0 Journal Article
%A Casanova, Ciro
%A Celli, Bartolome R.
%A de-Torres, Juan P.
%A Martinez-Gonzalez, Cristina
%A Cosio, Borja G.
%A Pinto-Plata, Victor
%A de Lucas-Ramos, Pilar
%A Divo, Miguel
%A Fuster, Antonia
%A Peces-Barba, German
%A Calle-Rubio, Myriam
%A Solanes, Ingrid
%A Aguero, Ramon
%A Feu-Collado, Nuria
%A Alfageme, Inmaculada
%A De Diego, Alfredo
%A Romero, Amparo
%A Balcells, Eva
%A Llunell, Antonia
%A Galdiz, Juan B.
%A Marin, Margarita
%A Moreno, Amalia
%A Cabrera, Carlos
%A Golpe, Rafael
%A Lacarcel, Celia
%A Soriano, Joan B.
%A Luis Lopez-Campos, Jose
%A Soler-Cataluna, Juan J.
%A Marin, Jose M.
%T Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD
%D 2017
%@ 0903-1936
%U http://hdl.handle.net/10668/19115
%X The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (>= 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.
%K Obstructive pulmonary-disease
%K Clinical characteristics
%K Inhaled corticosteroids
%K Exacerbations
%K Asthma
%K Fluticasone
%K Guidelines
%K Biomarker
%K Efficacy
%K Dyspnea
%~